35,730 Amgen Inc. $AMGN Shares Acquired by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 88.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,992 shares of the medical research company's stock after buying an additional 35,730 shares during the period. Crossmark Global Holdings Inc.'s holdings in Amgen were worth $32,031,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. raised its position in Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock worth $17,874,974,000 after acquiring an additional 2,261,544 shares during the period. State Street Corp grew its position in shares of Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Amgen by 12.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company's stock valued at $1,952,156,000 after purchasing an additional 605,928 shares during the period. Bank of America Corp DE purchased a new stake in shares of Amgen during the second quarter worth about $1,831,903,000. Finally, Amundi increased its stake in shares of Amgen by 15.2% during the second quarter. Amundi now owns 3,890,189 shares of the medical research company's stock worth $1,408,715,000 after purchasing an additional 512,883 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by insiders.

Amgen Price Performance

Amgen stock opened at $438.34 on Thursday. The company has a fifty day simple moving average of $416.63 and a 200-day simple moving average of $376.69. The firm has a market capitalization of $236.98 billion, a price-to-earnings ratio of 19.62, a PEG ratio of 3.21 and a beta of 0.41. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 52-week low of $288.00 and a 52-week high of $447.03.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company's revenue for the quarter was up 9.5% on a year-over-year basis. During the same period last year, the firm posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts anticipate that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen's dividend payout ratio is currently 62.65%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Mizuho upped their price target on shares of Amgen from $303.00 to $352.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 18th. Wells Fargo & Company lowered their price objective on Amgen from $435.00 to $430.00 and set an "equal weight" rating on the stock in a report on Monday, October 12th. Canaccord Genuity Group boosted their price objective on Amgen from $366.00 to $384.00 and gave the stock a "hold" rating in a research note on Wednesday, August 5th. Sanford C. Bernstein boosted their price objective on Amgen from $335.00 to $345.00 and gave the stock a "market perform" rating in a research note on Thursday, August 6th. Finally, Guggenheim reduced their target price on Amgen from $388.00 to $378.00 and set a "neutral" rating for the company in a report on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Amgen presently has an average rating of "Hold" and a consensus target price of $388.64.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire delivered strong Phase 3 results. Amgen and AstraZeneca reported that Tezspire produced statistically significant improvements in eosinophilic esophagitis, including sustained symptom improvement and histologic remission through 52 weeks. Reuters reported a 69% remission rate, strengthening the case for a potential expansion of Tezspire beyond asthma. Reuters Tezspire Phase 3 results
• Positive Sentiment: Analysts remain bullish. Piper Sandler maintained a Buy rating and set a $457 price target, while Goldman Sachs raised its target to $481. The revisions indicate continued confidence in Amgen’s pipeline, earnings outlook and portfolio diversification. Piper Sandler Amgen rating
• Positive Sentiment: Recent financial performance supports the growth narrative. Amgen’s latest quarterly results exceeded expectations, with earnings per share of $6.29 versus the $5.62 consensus and revenue of $10.05 billion versus $9.43 billion expected. Revenue increased 9.5% year over year, helping reinforce the investment story. Amgen earnings beat analysis
• Neutral Sentiment: Additional catalysts are approaching. Amgen plans to present oncology data and other research at the European Society for Medical Oncology Congress on October 24, which could provide further pipeline updates. Amgen ESMO 2026 presentation
• Negative Sentiment: Valuation and execution risks remain. Amgen trades at a considerably higher valuation than Bristol Myers Squibb, according to comparative coverage, leaving less room for disappointment. Tezspire’s opportunity also depends on regulatory approval and successful commercialization in EoE. Amgen versus Bristol Myers Squibb comparison

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.